Systemic Antibiotics for Respiratory Infections

Introduction to Systemic Antibiotics

Systemic antibiotics, including amoxicillin, amoxicillin-clavulanate, cephalosporins, macrolides, fluoroquinolones, and tetracyclines, are administered orally or parenterally to treat various bacterial infections throughout the body, as recommended by the Infectious Diseases Society of America 1, 2

Amoxicillin is a reference compound for respiratory infections, effective against Streptococcus pneumoniae and other common respiratory pathogens, according to the American Academy of Pediatrics 1
Amoxicillin-clavulanate is recommended for respiratory infections with suspected beta-lactamase producing organisms like Haemophilus influenzae and Moraxella catarrhalis, as suggested by the Infectious Diseases Society of America 2
First generation cephalosporins are an alternative to amoxicillin for certain infections, as stated by the American College of Chest Physicians 1
Second generation cephalosporins, such as cefuroxime-axetil, are used for respiratory infections, as recommended by the Infectious Diseases Society of America 2
Third generation cephalosporins, including cefpodoxime-proxetil, cefotiam-hexetil, and cefixime, are used for specific indications, as suggested by the American Academy of Pediatrics 1, 2

Macrolides are used as alternatives in patients with beta-lactam allergies or for specific pathogens, according to the American College of Chest Physicians 1
Pristinamycin is an alternative for patients with beta-lactam allergies, as stated by the Infectious Diseases Society of America 1
Telithromycin is used in specific respiratory infections when other options are not suitable, as recommended by the American Thoracic Society 3

Doxycycline is an alternative treatment for respiratory infections, particularly in patients with beta-lactam allergies, as suggested by the Infectious Diseases Society of America 1

Respiratory fluoroquinolones, such as levofloxacin and moxifloxacin, are active against pneumococci and recommended as second-line agents for respiratory infections, according to the American College of Chest Physicians 1, 2
Older fluoroquinolones, including ofloxacin and ciprofloxacin, have limited activity against pneumococci and are not recommended for respiratory infections, as stated by the Infectious Diseases Society of America 2

Systemic antibiotics should be selected based on suspected pathogens, local resistance patterns, and patient factors, as recommended by the Infectious Diseases Society of America 1, 2
The duration of therapy varies by indication, with 5-10 days for most respiratory infections and 14 days for pneumonia, as suggested by the American College of Chest Physicians 3, 4
Therapeutic efficacy should be assessed within 48-72 hours of initiating treatment, according to the American Thoracic Society 3

Inappropriate use of fluoroquinolones for conditions where other antibiotics would be more appropriate can lead to antimicrobial resistance, as stated by the Infectious Diseases Society of America 2
Not adjusting therapy based on culture results when available can lead to treatment failure, according to the American College of Chest Physicians 3